Recent findings from our group demonstrate that the presence of tau in early Braak regions may have high sensitivity for capturing the risk of cognitive decline, whereas the accumulation of tau in more advanced Braak regions is associated with greater memory dysfunction.16 Thus, clinical trials focusing on the symptomatic phases of Alzheimer’s disease may wish to stratify subjects based on the presence of tau-PET abnormalities in more advanced Braak stages. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.